Apex Labs Ltd.

Symbol: Private
Market Cap: Private
Sector: Pharmaceuticals

APEX’s clinical development program is focused on Veterans – a population disproportionately affected by mental health conditions. The Company’s lead clinical candidate is a low-dose synthetic psilocybin product for the treatment of Post-Traumatic Stress Disorder (PTSD) and treatment resistant depression.

APEX’s strategy is to develop drug products including Active Pharmaceutical Ingredients (API) produced by chemical synthesis, and also drug products with botanically sourced API, differentiating APEX by diversifying APEX’s options for development and commercialization of drug products.